Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 19:45:108683.
doi: 10.1016/j.dib.2022.108683. eCollection 2022 Dec.

Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy

M Klingebiel  1 , C Arsov  2 , T Ullrich  1 , M Quentin  1 , R Al-Monajjed  2 , D Mally  2 , L M Sawicki  1 , A Hiester  2 , I Esposito  3 , P Albers  2 , G Antoch  1 , L Schimmöller  1
Affiliations

Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy

M Klingebiel et al. Data Brief. .

Abstract

This is a data article from the original publication "Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy" [1]. From January 2014 to April 2019 a sample collective of 785 patients with 3T multiparametric magnetic resonance imaging (mp-MRI) of the prostate and subsequent combined systematic biopsy (SB) and magnetic resonance imaging/ultrasound (US) fusion-guided biopsy (TB) was retrospectively analyzed. Prostate cancer (PCa) detection by TB and/or additional SB was analyzed.

Keywords: Imaging guided biopsy; Multiparametric magnetic resonance imaging; Pathology; Prostatic neoplasms.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships which have or could be perceived to have influenced the work reported in this article.

Figures

Fig 1
Fig. 1
Flowchart.
See this image and copyright information in PMC

References

    1. Klingebiel M, Arsov C, Ullrich T, et al. Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy. Eur. J. Radiol. 2021;137 doi: 10.1016/j.ejrad.2021.109587. - DOI - PubMed
    1. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur. Urol. 2016;69(1):16–40. doi: 10.1016/j.eururo.2015.08.052. - DOI - PMC - PubMed
    1. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur. Urol. 2019;76(3):340–351. doi: 10.1016/j.eururo.2019.02.033. - DOI - PubMed
    1. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 2016;40(2):244–252. doi: 10.1097/PAS.0000000000000530. - DOI - PubMed

LinkOut - more resources